Bedaquiline is a diarylquinoline antimycobacterial used in combination with other antibacterials to treat pulmonary multidrug resistant tuberculosis (MDR-TB). Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline.
- Mechanism
- Curator reviewed · 1 reference
Bedaquiline is a diarylquinoline antimycobacterial drug that inhibits mycobacterial ATP (adenosine 5'-triphosphate) synthase, by binding to subunit c of the enzyme that is essential for the generation of energy in M. tuberculosis..
- Primary indication
- Bedaquiline is indicated as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis resistant...Curator reviewed · 1 structured indication
- Formula / weight
- C32H31BrN2O2 · 555.505 g/mol (avg)
- First approval
- United States, 2012 · European Union, 2016
- Code names
- AIDS222089 · R-207910 · TMC-207
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
QUIJNHUBAXPXFS-XLJNKUFUSA-NSMILESCOC1=NC2=C(C=C(Br)C=C2)C=C1[C@@H](C1=CC=CC=C1)[C@@](O)(CCN(C)C)C1=CC=CC2=C1C=CC=C2Targets
What you can answer from here — as of September 23, 2026
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Bedaquiline, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account